As a model system, a series of water-soluble 9-anili-
noacridines was synthesized from commercially available
anthranilic acid and 2-bromobenzoic acid, via a 4-carboxylic
acid acridone intermediate.13 Reaction of the acridone with
thionyl chloride followed by a mild and selective hydrolysis
of the acyl chloride intermediate led to the formation of
9-chloro-4-carboxylic acid acridine. Reaction with an ap-
propriate aromatic amine (p-aminobenzoic acid, aniline,
p-sulfanilic acid, or 2,3-xylidine) finally afforded the desired
9-anilinoacridines of interest.14 All four 9-aminoacridines
proved stable in aqueous potassium phosphate buffer (100
mM, pH 7.4). Their reactivity with respect to other aromatic
amines was then investigated (Scheme 1). In a typical
experiment, a solution of acridine (50 µM) in potassium
phosphate buffer (100 mM, pH 7.4) was reacted with a
mixture of four aromatic amines (15 mM each, 300 equiv),
and the reaction was monitored by LC-MS.
Figure 1. Structures of the two anticancer agents m-AMSA and
BRACO-19.
The anticancer activity of 9-aminoacridines is clearly
established in vitro, and selected molecules have also been
successfully tested in vivo.10 However, although rarely
commented upon, the relative instability of this class of
molecules is also well established.11 While 9-alkylami-
noacridines can readily hydrolyze at alkaline pH to generate
the corresponding acridone, it was also recently shown that
9-aminoacridines can undergo partial amine exchange reac-
tion in organic solutions.12
When either 9-anilino-4-carboxyacridine (A3) or 9-sulfa-
nylo-4-carboxyacridine (A1) were reacted with a mixture of
aniline, p-aminobenzoic acid, p-sulfanilic acid, and 2,3-
xylidine, the slow formation of all four 9-aminoacridines was
observed until equilibrium was reached after 6 days (Figure
2). Although all four possible 9-aminoacridines were ob-
Scheme 1. General Principle for Reversible Synthesis of Four
9-Aminoacridines, A1-A4, from 9-Anilino and 9-Sulfanylo
Acridine
Figure 2. HPLC traces of an equilibrating mixture of 50 µM
9-anilinoacridine A3 (left) or 9-sulfaniloacridine A1 (right) in
potassium phosphate buffer (100 mM, pH 7.4) containing a mixture
of p-aminobenzoic acid, aniline, p-sulfanilic acid, and 2,3-xylidine
(15 mM each). All mixtures were analyzed by LC-MS at t ) 0
(black), 3 days (red), and 6 days (blue).
Herein, we report that water-soluble 9-aminoacridines can
undergo a reversible and thermodynamically controlled
amine exchange reaction under near-physiological aqueous
conditions, which has potential implications for the under-
standing of the possible mode of action of 9-aminoacridines
in vivo and on the future design of acridine-based therapeutic
agents.
served in both reactions, they were not present at equilibrium
in identical proportions: A3 > A2 ≈ A4 > A1 (Figure 2).
However, the same distribution was obtained when starting
from either the 9-anilino (A3) or the 9-sulfanilic acid (A1)
acridine, thus demonstrating that this amine exchange
reaction is reversible and under thermodynamic control.
Because of the possibility for 9-aminoacridines to coexist
in solution with their tautomeric imino form, we propose
that the amine exchange reaction proceeds reversibly via
formation of a 9,9-diaminoacridine hemiaminal intermediate
(Scheme 2). This mechanism is in agreement with that
proposed by Bierbach et al. to explain the formation of
unusual 9-spirocyclic acridines.15 However, formation of this
unstable intermediate can proceed either via a SNAr-like
mechanism or via a transimination reaction depending on
whether the reactive species is the amino or the imino
acridine, respectively.
(9) (a) Sundquist, W. I.; Bancroft, D. P.; Lippard, S. J. J. Am. Chem.
Soc. 1990, 112, 1590. (b) Su, T. L.; Lin, Y. W.; Chou, T. C.; Zhang, X.;
Bacherikov, V. A.; Chen, C. H.; Liu, L. F.; Tsai, T. J. J. Med. Chem. 2006,
49, 3710. (c) Ma, Z.; Rao, L.; Bierbach, U. J. Med. Chem. 2009, 52, 3424.
(10) (a) Burger, A. M.; Dai, F.; Schultes, C. M.; Reszka, A. P.; Moore,
M. J.; Double, J. A.; Neidle, S. Cancer Res. 2005, 65, 1489. (b) Oppegard,
L. M.; Ougolkov, A. V.; Luchini, D. N.; Schoon, R. A.; Goodell, J. R.;
Kaur, H.; Billadeau, D. D.; Ferguson, D. M.; Hiasa, H. Eur. J. Pharmacol.
2009, 602, 223.
(11) (a) Su, T. L.; Chou, T. C.; Kim, J. Y.; Huang, J. T.; Ciszewska,
G.; Ren, W. Y.; Otter, G. M.; Sirotnak, F. M.; Watanabe, K. A. J. Med.
Chem. 1995, 38, 3226. (b) Goodell, J. R.; Svensson, B.; Ferguson, D. M.
J. Chem. Inf. Model. 2006, 46, 876.
(12) Sebest´ık, J.; Safar´ık, M.; Stibor, I.; Hlava´cek, J. Biopolymers 2006,
84, 605.
Org. Lett., Vol. 11, No. 21, 2009
4895